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Abstract
Background: We conducted a cohort study to compare the characteristics of MDR-TB with non-MDR-TB patients
and to measure long term (9-year) mortality rate and determine factors associated with death in China.
Methods: We reviewed the medical records of 250 TB cases from a 2001 survey to compare 100 MDR-TB patients
with 150 non-MDR-TB patients who were treated in 2001-2002. Baseline attributes extracted from the records were
compared between the two cohorts and long-term mortality and risk factors were determined at nine-year follow-
up in 2010.
Results: Among the 234 patients successfully followed up, 63 (26.9%) were female and 171 (73.1 %) were male.
MDR-TB patients had poorer socioeconomic status compared to non-MDRTB. Nine years after the diagnosis of TB,
69 or 29.5 % of the 234 patients had died (32 or 21.6 % of non-MDR-TB versus 37 or 43.0 % of MDR-TB) and the
overall mortality rate was 39/1000 per year (PY) (27/1000 PY among non-MDR versus 63/1000 PY among MDR-TB).
Factors associated with death included: MDR status (hazard ratio (HR): 1.86; CI: 1.09-3.13), limited education of
primary school or lower (HR: 2.51; CI 1.34-4.70) and received TB treatment during the nine-year period (HR 1.82;
95 % CI 1.02-3.26).
Conclusions: MDR-TB was a strong predictor for poor long-term outcome. High quality diagnosis and treatment
must be ensured. Greater reimbursement or free treatment may be needed to provide access for the poor and
vulnerable populations, and to increase treatment compliance.
Background
Multidrug-resistant tuberculosis (MDR-TB) is resistant
to isoniazid (H) and rifampicin (R). MDR-TB is a major
barrier to TB control, especially in high burden coun-
tries such as China [1]. Despite impressive reductions in
TB prevalence and mortality over the past 20 years,
the World Health Organization (WHO) estimates that
China has the second largest number of MDR-TB
cases globally; only India has more cases [2]. The national
baseline TB survey in 2007–2008 found that 8 · 3 % of
cases were MDR-TB, predicting approximately 120,000
new MDR-TB cases annually [3].
MDR-TB requires prolonged treatment with costly
second-line anti-TB drugs (SLD), leading to health sys-
tem opportunity costs, adverse effects, and financial im-
pacts for patients [4–6]. Patients with MDR-TB have a
low treatment success rate: 48 % globally and 50 % in
China [7]. Recurrence and treatment failure are more
common for drug resistant than drug sensitive TB
[8–10], however, little is known of the impact of mul-
tidrug resistance on long-term mortality and survival.
We conducted a follow-up study nine years after diag-
nosis with TB or MDR-TB in Henan Province, China to
compare characteristics and mortality of MDR and non-
MDR-TB patients. Our study sample was drawn from a
representative drug resistance surveillance (DRS) study
conducted in 2001 in Henan. We chose Henan because
it had the second largest number of TB and MDR-TB
cases and a high quality DRS in 2001. All culture-
verified patients were identified in 2001, treated with
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first-line drugs (FLDs) through directly-observed treat-
ment, short-course (DOTS) between 2001 and 2002, and
surveyed in 2002 and again in 2010. We report long
term outcome and hazard ratio data for death by com-
paring two cohorts: MDR-TB patients and non-MDR-TB
patients.
Methods
Study design
We conducted a cohort study followed up TB and
MDR-TB patients nine years after diagnosis with the
disease in Henan Province, China.
Study setting
Henan Province is in the middle of China and had a
population of 99.1 million people in 2010 [11]. Although
the incidence of TB in Henan (71.1 per 100,000 in 2010)
is close to the Chinese average, the absolute number of
TB cases reported in 2012 (68,042) was the second high-
est among all provinces [11]. DOTS, as recommended
by WHO, has been implemented progressively in Henan
Province since 1996, reaching 100 % coverage in 2005.
Study population and field procedure
In 2001, WHO supported a DRS that was conducted in
Henan Province. A total of 1854 newly registered, spu-
tum smear-positive cases from 30 of 159 counties and
districts who had been treated between July 2001 and
June 2002 were selected at random from the DRS and
resurveyed. The survey methods, findings, and culture
results of the 1487 cases who had culture results and
complete medical records are reported elsewhere [12].
Those 1487 cases included 192 culture-proven MDR-TB
patients and 1295 non-MDR-TB patients [12]. All pa-
tients were eligible to be included in the follow-up study;
100 MDR-TB patients and 150 non-MDR-TB patients in
17 counties were randomly selected, based on power
calculations (Figs. 1 and 2). The study was powered to
detect a 2-fold increased risk of death over 10 years be-
tween the MDR and the non-MDR groups, with 2-tailed
significance of 0.05 and a power of 0.8, assuming 20 %
mortality in the MDR-TB group. Non-MDR patients
were oversampled in a ratio of 1.5:1 to accommodate
greater difficulty tracking non-MDR patients. The mini-
mum sizes of the required samples were 112 non-MDR
patients and 75 MDR patients; sample sizes were increased
proportionately to 150 and 100 patients, respectively, to
account for patients being lost to follow up.
In 2010, we followed up the 250 randomly-sampled
patients. We extracted data on demographics, treatment
history, DST results, and treatment outcomes from the
DRS. All information was re-checked against patients’
medical records, with few discrepancies being found.
Discrepancies that were discovered were resolved with
information from county or district TB dispensaries. A
questionnaire was developed based on the aims of the
follow up study. Interviews were conducted at infor-
mants’ homes or at clinics from January to May 2010.
Sputum status was extracted from laboratory and med-
ical records in county or district anti-TB departments. If
a patient had been reported to have died after comple-
tion of treatment in 2002, information on date and cause
of death was collected. If the patient could not be inter-
viewed because they had died, moved out of the home,
Fig. 1 Simple random sampling processes for selecting study population in 2010
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or were absent from the home when the interview was
conducted, we interviewed family members, neighbours,
village doctors, and other village leaders to collect the
required information. We were unable to contact 14 of
the 100 MDR-TB patients, and we excluded two of the
150 non-MDR-TB patients due to poor data quality. The
final dataset included 86 MDR-TB and 148 non-MDR-
TB patients.
Treatment regimens and outcomes
Treatment regimens followed the Chinese National Tu-
berculosis Control program (NTP) treatment guidelines,
as recommended by WHO. Treatment of new smear-
positive patients consisted of two months of H, R,
pyrazinamide (Z), and ethambutol (E) followed by four
months of H and R three times weekly. Patients who
had previously received at least one month of TB treat-
ment (i.e. retreatment patients) received two months of
H, R, Z, S and E, followed by six months of H, R, and E
three times weekly. Drug administration was observed at
the health facility throughout treatment. The treatment
regimens and outcomes have been presented in detail
elsewhere [13]. Treatment outcomes were assessed using
WHO definitions [14].1
Data management and statistical analysis
All data were double entered in EpiData 3.1 (The Epi-
Data Association, Odense, Denmark, 2008), and internal
Fig. 2 Geographical location of counties surveyed in Henan Province, 2001 & 2010
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consistency was determined. Internal discrepancies were
checked against the original forms by the first author.
Statistical inference followed standard procedures for
categorical data [15]. Pearson’s χ2 test or Fisher’s exact
test was used for testing differences in proportions.
Two-sided distribution p-values of <0.05 were consid-
ered significant. The overall mortality rate was calcu-
lated, as well as that specific to the two groups (MDR
and non-MDR-TB), expressed in terms of cases per 1000
person-year (PY) of follow-up and at two-year intervals.
The follow-up period from the date of DOTS TB treat-
ment completion until death, transfer, completion of fol-
low-up, or the end of the study was computed as the
time elapsed since the end of TB treatment. A Cox
proportional hazards regression was performed with
time dependant covariates in relation to TB death;
a forward inclusion approach was used. Variables
significantly correlated in the unadjusted model with
p-value <0.05 and those of epidemiological interest
were included into the multivariable model. Hazard
ratios (HR) with their 95 % confidence intervals (CI) were
used to measure association. Survival curves, unadjusted
and adjusted by age and other covariates over drug
resistance status, were plotted. Stata software (Version
12; Statacorp) was used for data analysis and prepar-
ation of graphs.
Ethical considerations
The original 2001 MDR-TB surveillance survey was
approved by the Ethics Committee of the Department of
Health of Henan Province based on Chinese national
ethical regulations. The follow-up study in 2010 was
approved by the Ethics Committee of the Tuberculosis
Control and Prevention Institute of Henan Provincial
Center for Disease Control and Prevention and by the
Human Research Ethics Committee of the Australian
National University on 12 November, 2009 (Protocol
2009/553, Appendix 2). Information sheets and consent
forms were provided to participants, and consent was
obtained from all study participants. Participation was
voluntary, and confidentiality of data was maintained.
Results
Attributes of the study population at baseline
A total of 234 patients, 86 MDR-TB and 148 non-MDR-
TB patients were identified and followed up. All were
reported to have completed treatment, and none were
HIV positive. Of the 86 MDR-TB and 148 non-MDR-TB
patients, the sex ratios and age structures were similar
(Table 1). Most (approximately 80.0 %) were married
and there was no significant difference in marital status
between the MDR and non-MDR-TB groups. A majority
(approximately 85 %) were farmers. The groups had simi-
lar educational attainment (44 · 1 % of MDR-TB versus
54 · 8 % of non-MDR-TB subjects attained middle-school
education or above, p = 0 · 19).
A greater proportion of MDR-TB patients were found
to be smokers after their diagnosis (34 · 9 % versus 18 · 9 %;
p < 0 · 01). There was no significant difference in alcohol
consumption. More MDR-TB than non-MDR-TB patients
worked following cure of their TB (9 · 3 % in MDR-TB
versus 2 % in non-MDR-TB; p < 0 · 01). Patients with
Table 1 Attributes of the study population by drug resistance
status at baseline, 2001-2002a
Patient attributes MDR-TB Non-MDR-TB p-value
n = 86 (%) n = 148 (%)
Sex
Male 64 (74.4) 107 (72.3) 0 · 72
Female 22 (25 · 6) 41 (27 · 7)
Age groups (years)
10 ~ 29 20 (23 · 3) 35 (23 · 6) 0.16
30 ~ 44 28 (32 · 6) 42 (28 · 4)
45 ~ 59 26 (30 · 2) 33 (22 · 3)
60~ 12 (13 · 9) 38 (25 · 7)
Marital status
Married 70 (81 · 4) 115 (78 · 2) 0 · 84
Othersb 16 (18 · 6) 32 (21 · 8)
Occupation
Farmers 75 (87 · 2) 125 (85 · 0) 0 · 29
Othersc 11 (12 · 8) 22 (15 · 0)
Education
≤ Primary school 48 (55 · 9) 66 (45 · 2) 0 · 19
≥Middle school 38 (44 · 1) 80 (54 · 8)
Smoker 30 (34 · 9) 28 (18 · 9) <0 · 01
Alcohol drinker 14 (16.3) 20 (13.5) 0.56
Work outsided for cash
after TB cured
8 (9 · 3) 3 (2 · 0) <0 · 01
Numbers of bedrooms in patients’ house
≥ 4 51 (62 · 2) 119 (82 · 1) <0 · 01
≤ 3 31 (37 · 8) 26 (17 · 9)
Annual household income (Yuan)
≥ 10 000 38 (44 · 7) 91 (61 · 9) 0 · 01
< 10 000 47 (55 · 3) 56 (38 · 1)
Community/government offered
financial help
13 (15 · 7) 12 (8 · 8) 0 · 24
Insurance
Insured 8 (10 · 5) 16 (11 · 0) 0 · 97
Own expense 77 (89 · 5) 130 (89 · 0)
aThose with missing values were excluded from the comparisons
bOthers include single, divorced, and widowed
cOthers include worker, cadre, teacher, student, self-employment, unemployed,
and housewife/homemaker
dPatient worked outside hometown for cash as a migrant worker
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MDR-TB were more likely to live in houses with fewer
than three bedrooms (37 · 8 % versus 17 · 9 %; p < 0.01).
MDR-TB households had lower income; 55 · 3 % had
annual household income less than 10,000 Chinese Yuan
compared to 38 · 1 % for households with non-MDR-TB
(p = 0 · 01). A higher percent of MDR-TB patients (15 · 7 %)
than non-MDR-TB patients (8 · 8 %) received some finan-
cial support from the local community or government.
Medical insurance was held by 10 · 5 % and 11 %, respect-
ively, in the MDR-TB and non-MDR-TB groups. Unin-
sured patients paid for their own TB treatment.
Mortality rates
The overall mortality rate of the followed up patients
was 39/1,000 PY (11/1,000 PY among those 10–29 years
of age, and 31, 52, and 75, respectively, for those aged
30–44, 45–59, and 60 years or above). The mortality was
27/1,000 PY among non-MDR-TB and 63/1,000 PY
among MDR-TB patients, respectively. The highest mor-
tality rates were found between the second and fourth
year after completion of treatment (53/1,000 PY), followed
by the fourth to sixth (48/1,000 PY), and the first two
years (42/1,000 PY). Mortality rates for non-MDR-TB and
MDR-TB patients in the first two years after the comple-
tion of treatment were 86 and 17/1,000 PY, respectively.
Attributes of the study population with regard to long
term survival by 2010
The median age of the study population was 49 years
(IQR 20–84). No significant difference was observed in
the ratio of males to females with TB. A statistically sig-
nificant difference in mortality between MDR and non-
MDR-TB patients was seen after 9 years (53.6 % versus
29.7 %; p = 0.001). A greater proportion of patients with
education lower than primary school died compared to
those with education level at middle school and above
(71.0 % versus 39.4 %; p = 0.03). More patients who lived
in houses with fewer than three bedrooms had died
(34.9 % versus 21.1 %; p = 0.03). Mortality was more
common in those with annual household incomes less
than 10,000 Yuan (60.3 % versus 37.8 %; p = 0.002). Pa-
tients who received TB treatment during the nine-year
period were more likely to die (33.9 % versus 16.6;
p = 0.005) (Table 2).
Factors associated with death
In unadjusted analysis, death was significantly associated
with age greater than 45 years, MDR-TB, lower level of
education, having fewer than three bedrooms in the
home, having an annual household income less than
10,000 Yuan, and having received TB treatment (Table 3).
In the multivariate analysis, death was significantly asso-
ciated with MDR (HR 1 · 86; 95 % CI 1 · 09-3 · 13), educa-
tional attainment of primary school or lower (HR 2 · 51;
95 % CI 1 · 34-4 · 70), and having received TB treatment
(HR 1.82; 95 % CI 1.02-3.26). The mean survival for
MDR-TB was 6.4 years compared to 7.7 years. The
survival curves are plotted by drug resistance status
unadjusted and then adjusted with statistically significant
covariates (Fig. 3).
Discussion
This study in Henan Province, China is, to the best of
our knowledge, the first comparison of long-term out-
comes and mortality between MDR-TB and non-MDR-
TB patients. We found that patients with MDR-TB had
poorer outcomes than non-MDR-TB patients. The sur-
vival time for MDR-TB patients was shorter than for
non-MDR-TB patients. We also found that drug resist-
ance status was a very strong predictor of mortality, as
was educational level attained. The provision of TB treat-
ment was also statistically significantly associated with
mortality.
Mortality in MDR-TB patients was approximately five-
fold higher than among the non-MDR-TB patients in
Table 2 Attributes of the study population by long term
survival to 2010a
Patient attributesb Total Survived Died p-value
n = 234 (%) n = 165 (%) n = 69 (%)
Median age (years) (IQRc) 49 (20–84) 46 (23–84) 58 (20–86) 0.003
Sex
Female 63 (26.9) 49 (29.7) 14 (20.3)
Male 171 (73.1) 116 (70 · 3) 55 (79 · 7) 0.14
Drug resistance status
Non-MDR-TB 148 (63.3) 116 (70 · 3) 32 (46 · 4)
MDR-TB 86 (36.7) 49 (29 · 7) 37 (53 · 6) 0.001
Education
≥Middle school 120 (51.3) 100 (60 · 6) 20 (29 · 0)
≤ Primary school 114 (48.7) 65 (39 · 4) 49 (71 · 0) <0.001
Number of bedrooms in patient’s home
≥ 4 170 (74.9) 127 (78 · 9) 43 (65 · 1)
≤ 3 57 (25.1) 34 (21 · 1) 23 (34 · 9) 0.03
Annual household income (Yuan)
≥ 10,000 129 (55.6) 102 (62 · 2) 27 (39 · 7)
< 10,000 103 (44.4) 62 (37 · 8) 41 (60 · 3) 0.002
Whether received TB treatment
No 172 (78.5) 131 (83.4) 41 (66.1)
Yes 47 (21.5) 26 (16.6) 21 (33.9) 0.005
aThose with missing values were excluded from the comparisons
bVariables also tested and found to have p value > 0.10 and not listed in the
table included the following: marital status, occupation, smoker after getting
TB, alcohol consumption, worked as a migrant worker after got TB cured, and
not received help from social welfare and insurance
cInterquartile range
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Henan, China by 2010. This MDR-TB mortality rate was
higher than rates reported from studies in other regions
and countries [8, 16, 17], perhaps because we followed
up patients over a longer period (9-years) than others
(3–6 years).
Increased age was not identified as a mortality risk fac-
tor in the final multivariable analysis in our study, unlike
findings from other studies [18, 19]. Older patients may
have delayed health care seeking, and diagnosis may also
have been delayed due to the nature of the clinical
Table 3 Factors associated with death in the study population, 2010a
Patient attributes Unadjusted HR p-value Adjusted HR p-value
(95 % CI) (95 % CI)
Male sex 1 · 50 (0 · 83-2 · 71) 0.17 1 · 39 (0 · 76-2 · 56) 0.28
Age groups (years)
≤ 44 1 1
45-59 2.02 (1.04-3.92) 0.04 1.46 (0.73-2.94) 0.28
60~ 2.82 (1.52-5.25) 0.001 1.80 (0.88-3.66) 0.10
Drug resistance status
Non-MDR-TB 1.00 1.00
MDR-TB 2 · 29 (1 · 41-3 · 71) 0.001 1 · 86 (1 · 09-3 · 13) 0.02
Education
≥Middle school 1.00 1.00
≤ Primary school 3 · 18 (1 · 84-5 · 46) <0.001 2 · 51 (1 · 34-4 · 70) 0.004
Number of bedrooms in patient’s home
≥ 4 1.00 1.00
≤ 3 1 · 7 (1 · 01-2 · 86) 0.04 0 · 99 (0 · 56-1 · 75) 0.97
Annual household income (Yuan)
≥ 10,000 1.00 1.00
< 10,000 2 · 09 (1 · 27-3 · 43) 0.004 1 · 50 (0 · 87-2 · 59) 0.14
Received TB treatment 2.12 (1.23-3.66) 0.007 1.82 (1.02-3.26) 0.04
aThose with missing values were excluded from the comparisons
Fig. 3 Survival analysis estimates of long-term survival based on drug resistance status
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presentation in older patients compared with younger pa-
tients. Poor immune function in older people may influ-
ence mortality [18, 20]. In our study, age was a risk factor
in unadjusted analysis, but did not remain significant in
multivariable analysis. This may be due to confounding of
age with educational attainment, household economic sta-
tus, and access to TB treatment during the nine-year
follow-up period. In our study, multidrug resistance was
one of the strongest risk factors for death, with a HR 1.86
times higher compared with non-MDR-TB. A similar
finding was reported from a study in Estonia [19, 21].
We found a significant association between lower edu-
cation and death in both unadjusted and multivariable
analyses—a finding that has not been reported elsewhere
[21–23]. Patients with less education may lack know-
ledge about health care access and the importance of
compliance with treatment. Low annual household in-
come was also found to be associated with death. Pov-
erty, low household economic status, and lack of health
insurance have all been reported as risk factors in previ-
ous studies [23].
Another key finding from our study was that a sub-
stantial proportion of MDR-TB patients had annual
household incomes less than 10,000 Yuan (≈1500 US
dollars). It is considered to be a catastrophic payment by
a household if a medical care charge is 40 % or more of
the household’s capacity to pay [24]. In the field evalu-
ation, we collected data on patient-reported treatment
costs. However, we did not analyse these data because
we could not determine direct and indirect medical
costs and losses of income from the respondents’ re-
ports. We strongly recommend that future studies
conduct economic analyses because TB is a disease of
poverty, and out-of-pocket payments could be an im-
portant predictor of treatment compliance and outcome.
This study has provided valuable information on the
high burden of TB and MDR-TB in Henan Province,
China. Unfortunately, we could not follow up all patients
in the 30 counties included in the baseline survey in
2001 to investigate patients’ out of pocket cost for treat-
ment. Efforts were made to select representative coun-
ties in the sample. A complete follow up study covering
all 30 counties in the province is recommended to evalu-
ate all surveyed patients in 2001 and determine fully
long term outcomes. Some of the information collected
in this study was based on self-report from respondents.
Annual household income and socioeconomic status
may have been underestimated. We designed our ques-
tionnaire and conducted field interviews to minimise
reporting bias.
Our study has important implications for TB control
in China and worldwide, especially for countries with
high TB burdens [5, 25, 26]. The much longer treatment
durations and the lower cure rates of MDR-TB,
compared with non-MDR-TB, pose continuing threats
to communities. Many recent studies indicate that drug-
resistant TB is transmitted primarily to healthy people
[27, 28] - despite a belief that drug resistant mycobac-
teria have lowered virulence and transmissibility. The
high death rate of MDR-TB puts a huge economic,
social, and psychological burden on patients, families,
and communities.
In 2014, the 67th World Health Assembly passed a
resolution approving the new post-2015 Global TB Strat-
egy, with its ambitious and unprecedented targets, and
with its vision of ending TB as an epidemic disease by
2035. Our study has demonstrated that MDR is a strong
predictor for mortality. Given this finding, as well as the
longer treatment period needed (hence a prolonged
period during which others in the community may be
infected), prevention and control of MDR-TB should be
the first priority in order to reach the targets.
Chinese TB control programs should target MDR-TB
patients because they are at great risk for death and poor
socioeconomic outcome. Treatment of drug-resistant TB
is being implemented by the NTP in some project areas
through the Global Fund to fight AIDS, Tuberculosis
and Malaria (GF). Five cities in Henan Province were
covered by GF projects including susceptibility testing
and treatment for MDR-TB. A challenge to the province
and to the whole country is that the GF stopped its sup-
port in China in June 2014. The Chinese administration
has already started to expand access to MDR-TB care with
diagnosis and treatment transferred to TB-designated hos-
pitals from the Chinese Centres for Disease Control and
Prevention. Clinicians who focus on individual cases need
time to embrace public health concepts and increase their
capacity for diagnosing and treating MDR-TB patients.
To alleviate the economic burden on TB patients, the
Chinese government has designated MDR-TB as one of
eight priority diseases eligible for 70 % reimbursement in
the country’s rural health insurance program. However,
the reimbursement proportion may need to be increased,
and additional financial assistance may need to be
provided to ensure that the poorest and most vulnerable
patients have access to care and are able to complete
their treatment.
The findings from this study highlight that MDR-TB is
a serious public health problem in China. Global Fund
support has permitted the scaling up of drug sensitivity
testing and multi-drug resistant treatment in 921 coun-
ties of 92 prefectures in China, but sustainability after
the Global Fund withdraws requires intensive Chinese
government support.
Conclusions
MDR-TB is a strong predictor for poor long-term out-
come. High quality diagnosis and treatment must be
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ensured. Greater reimbursement or free treatment may
be needed to provide access for the poor and vulnerable
populations, and to increase treatment compliance.
Endnote
1Treatment success was defined as either cure or treat-
ment completed. Cure was defined as a patient whose
sputum smear or culture was positive at the beginning
of the treatment but smear- or culture-negative in the
last month of treatment and on at least one prior occa-
sion. Treatment completed did not need to meet the cri-
teria for cure or failure. Failure was defined as sputum
smear-positive at 5 months or later during treatment.
Death was defined as a patient who died for any reason
during the course of treatment (the cause of death
during TB treatment was not recorded).
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